Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $16.60

NeuroPace, Inc. (NASDAQ:NPCE) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $17.3333.

NPCE has been the topic of several analyst reports. Leerink Partners reissued an “outperform” rating and set a $19.00 price objective on shares of NeuroPace in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 target price on shares of NeuroPace in a research report on Wednesday. Wells Fargo & Company increased their price target on NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday. Zacks Research lowered shares of NeuroPace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research note on Wednesday, October 8th.

Hedge Funds Weigh In On NeuroPace

A number of large investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC grew its position in NeuroPace by 194.2% in the 3rd quarter. Essex Investment Management Co. LLC now owns 216,722 shares of the company’s stock valued at $2,234,000 after acquiring an additional 143,063 shares during the last quarter. Western Wealth Management LLC purchased a new stake in shares of NeuroPace during the third quarter valued at $237,000. Principal Financial Group Inc. grew its holdings in shares of NeuroPace by 118.7% in the third quarter. Principal Financial Group Inc. now owns 39,504 shares of the company’s stock worth $407,000 after purchasing an additional 21,439 shares during the last quarter. AlphaQuest LLC grew its holdings in shares of NeuroPace by 131.5% in the third quarter. AlphaQuest LLC now owns 17,087 shares of the company’s stock worth $176,000 after purchasing an additional 9,707 shares during the last quarter. Finally, Lazard Asset Management LLC increased its stake in NeuroPace by 2,445.5% in the 2nd quarter. Lazard Asset Management LLC now owns 78,885 shares of the company’s stock worth $878,000 after buying an additional 75,786 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Stock Down 1.5%

Shares of NPCE opened at $12.78 on Friday. The stock has a market capitalization of $425.70 million, a price-to-earnings ratio of -16.82 and a beta of 1.90. NeuroPace has a 1 year low of $6.63 and a 1 year high of $18.98. The business’s 50 day simple moving average is $10.29 and its 200-day simple moving average is $10.86. The company has a debt-to-equity ratio of 3.17, a current ratio of 4.86 and a quick ratio of 4.51.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 136.60%. The business had revenue of $27.35 million during the quarter, compared to analysts’ expectations of $24.64 million. NeuroPace has set its FY 2025 guidance at EPS. As a group, equities analysts expect that NeuroPace will post -1 earnings per share for the current fiscal year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.